Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil

Silva, Thiago Cerqueira; Andrews, Jason R.; Boaventura, Viviane S.; Ranzani, Otavio T.; Oliveira, Vinicius de Araújo; Paixão, Enny S.; Bertoldo Júnior, Juracy; Machado, Tales Mota; Hitchings, Matt D.T.; Dorion, Murilo; Lind, Margaret L.; Penna, Gerson Oliveira; Cummings, Derek A.T.; Dean, Natalie E.; Werneck, Guilherme Loureiro; Barreto, Maurício Lima; Ko, Albert Icksang; Croda, Julio; Barral Netto, Manoel.
Preprint en Inglés | PREPRINT-FIOCRUZ | ID: ppf-50655

Documentos relacionados

  1. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
  2. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  3. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
  4. Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults.
  5. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
  6. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
  7. Efficacy and safety of COVID-19 vaccines.
  8. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
  9. Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
  10. Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine.